Alnylam Pharma Submits CTA To Initiate Phase 1/2 Study Of ALN-AAT02

Shutterstock photo

(RTTNews.com) - Alnylam Pharmaceuticals, Inc. ( ALNY ) announced it has submitted an Clinical Trial Authorization application to the Medicines and Healthcare products Regulatory Agency to initiate a Phase 1/2 study of ALN-AAT02, an investigational RNAi therapeutic targeting alpha-1 antitrypsin for the treatment of alpha-1 antitrypsin deficiency-associated liver disease.

Thomas Hoock, Vice President, Program Lead for ALN-AAT02 at Alnylam, stated: "We are also excited for ALN-AAT02 to enter the clinic as the first investigational RNAi therapeutic that will leverage the significant enhancements we have made to our GalNAc-siRNA conjugate platform. Pending feedback from the MHRA, we look forward to evaluating the safety, pharmacodynamics, and clinical activity of this molecule in a Phase 1/2 study in healthy volunteers and adults with alpha-1 liver disease, which we expect to initiate by year-end 2018."

Read the original article on RTTNews (http://www.rttnews.com/2940474/alnylam-pharma-submits-cta-to-initiate-phase-1-2-study-of-aln-aat02.aspx)

For comments and feedback: contact editorial@rttnews.com

This article appears in: World Markets , Stocks , Technology
Referenced Symbols: ALNY

More from RTT News


See All RTT news

Research Brokers before you trade

Want to trade FX?